Azelastin (When ATH R01AC03)

When ATH:
R01AC03

Characteristic.

Phthalazinone derivative. Limited soluble in water, methyl alcohol and propylene glycol, slightly soluble in ethyl, octyl alcohol and glycerol.

Pharmacological action.
Antihistamine, antiallergic, membrane stabilizing.

Application.

Allergic rhinitis and conjunctivitis (Seasonal, year-round).

Contraindications.

Hypersensitivity, pregnancy, lactation, childhood (eye drops-to 4 years, nazalny sprays-up to 6 years).

Pregnancy and breast-feeding.

Contraindicated in pregnancy (especially in the I trimester).

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

At the time of treatment should stop breastfeeding.

Side effects.

Allergic reactions: skin rash, hives, itch.

From the respiratory system: sneezing attacks, pharyngitis, cough, breathlessness, a feeling of tightness in the chest, labored breathing, bronchospasm.

From the nervous system: headache, dizziness, fatigue.

From the digestive tract: bitter taste in the mouth (19,7%), change in taste, dry mouth, nausea, gastralgia.

Other: tachycardia, hematuria, myalgia, weight gain; in ispolyzovanii nazalynogo spray: drowsiness (11,5%), dryness, irritation, burning or itching of the nasal mucosa; rarely — nosebleeds; during application of eye drops: conjunctival irritation; rarely — dry eyes, lacrimation, foreign body sensation or pain in the eye, edema, xemoz, bleeding in the anterior chamber of the eye, keratopatiâ / keratit, erosion or excoriation of the cornea, blurred vision, .Aloe.

Cooperation.

Strengthens (mutually) sedative effects of alcohol and other means, CNS depressants. Ketoconazole inhibits certain concentration of azelastine in plasma, and cimetidine, ugnetaya cytochrome P450, it increases.

Overdose.

Symptoms: likely hypersomnia.

Treatment: symptomatic.

Dosing and Administration.

Spray nazalynыy: intranasally (pre-clearing the nasal passages): by 1 spray (0,14 0.14 mg/ml) in each nostril 2 twice a day until symptoms of the disease. The course of treatment no more 6 Months.

Eye drops: conjunctivally on 1 drop in each eye in the morning and evening until disappearance of symptoms. If necessary, the dose is increased to four times a day by one drop to each eye.

Precautions.

With care prescribe a nasal spray in patients with impaired renal function. When using the spray should not throw back his head back. During treatment to avoid alcohol and the use of funds, CNS depressants. Keep in mind the possibility of dizziness and drowsiness.

Cautions.

When using an eye drop is not suitable for wearing contact lenses.

Azelastin (eye drops) It can be used for treatment of infectious eye diseases only in the complex therapy on doctor's advice.

Cooperation

Active substance	Description of interaction
Buspirone	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Haloperidol	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Droperidol	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Zolpidem	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Quetiapine	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Ketamine	FMR: synergism. Strengthens (mutually) CNS depression.
Clemastine	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions; Avoid simultaneous use.
Klozapyn	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Codeine	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Lorazepam	FMR: synergism. Enhanced CNS depression: reduced the rate of psychomotor reactions.
Midazolam	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Morphine sulfate	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Oxazepam	FMR: synergism. Enhanced CNS depression: reduced the rate of psychomotor reactions.
Olanzapine	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Perfenazyn	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Risperidone	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Tioridazin	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Trifluoperazine	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Phenobarbital	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Fentanyl	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Flufenazin	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Xlordiazepoksid	FMR: synergism. Enhanced CNS depression: reduced the rate of psychomotor reactions.
Chlorpromazine	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Chlorprothixene	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions.
Ethanol	FMR: synergism. Strengthens (mutually) CNS depression: reduced the rate of psychomotor reactions; H at the reception1-antihistamines, incl. azelastine, should exclude alcohol.